Current status and future perspective of gene therapy products in Japan

Maruyama, Yoshiaki; Sakurai, Akira; Kasai, Masaki; Noda, Shinichi; Honda, Futaba

doi:10.18609/cgti.2021.026

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cartagena Act is a law that covers the use of LMOs as pharmaceuticals in Japan. 17 In line with this, the use of Delytact Injection falls under Type 1 Use of genetically modified living organisms under Article 4 of the Cartagena Act, and approval for the provisions under Type 1 Use of genetically modified living organisms under Article 4 of the Cartagena Act has been obtained (Approval number, 14-36V-0002).…”

Section: Discussionmentioning

confidence: 96%

Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma

et al. 2023

Self Cite

View full text Add to dashboard Cite

In June 2021, the Ministry of Health, Labor and Welfare approved Delytact Injection as a regenerative medical product for oncolytic virus therapy. The active substance of Delytact Injection is teserpaturev, a genetically engineered herpes simplex virus type 1 (strain F) in which the α47 gene and both copies of the γ34.5 gene have been deleted and the infected cell protein 6 (ICP6) gene has been inactivated by the insertion of the lacZ gene from Escherichia coli. Delytact Injection, when intratumorally administered to patients with malignant glioma, is expected to exert the following effects: (1) the mutant virus selectively replicates in tumor cells and destroys the infected cells through the replication process, exerting a cytocidal effect, and (2) the administration leads to induction of tumor-responsive T cells, which activates antitumor immunity and thus prolongs the survival of patients with malignant glioma. A Japanese phase II study (Study GD01) was conducted in patients with glioblastoma who had residual or recurrent tumors after radiotherapy with concomitant temozolomide. In Study GD01, however, stable disease continued for an extended period in some patients with glioblastoma. Hence, Delytact Injection is expected to be effective to a certain level. In line with this, Delytact Injection has been approved as an option for the treatment of malignant glioma, with one of the 3 approval conditions including conducting a use-results comparison survey and resubmission of the marketing authorization application within the granted time period of 7 years, under the conditional and time-limited approval scheme described in Article 23–26 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

show abstract

Section: Discussionmentioning

confidence: 96%

Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…In response to comments that the review of the Cartagena process was complicated and time consuming, the PMDA established consultation schemes for the Cartagena Act in 2019. 52 , 53 Additionally, in 2019, mock-ups of the Type 1 Use Regulation Form for AAV, 41 herpes simplex viruses, and adenoviruses, 42 and in 2021, a mock-up of the Biological Diversity Impact Assessment Form for AAV were created, 39 which significantly increased the understanding of the information required for the application. Furthermore, in 2021, the MHLW changed the timing of approval for the Type 1 Application from before submission of the first clinical trial protocol application to before the initiation of the first clinical trial in Japan.…”

Section: Discussionmentioning

confidence: 99%